Skip to main content

Table 2 Time-averaged analysis: mean changes from baseline

From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

Endpoint Parameter Placebo (N = 50) NEPA200/0.5(N = 48) NEPA600/1.5(N = 49) Moxifloxacin (N = 49)
Change from baseline Change from baseline Placebo-corrected change from baseline Change from baseline Placebo-corrected change from baseline Change from baseline Placebo-corrected change from baseline
Primary QTcI, ms –2.1 2.6 4.7 1.5 3.6 6.3 8.4
  (Min;max) (−8.3; 4.8) (−5.8; 30.6)   (−7.3; 14.3)   (−2.6; 15.3)  
Secondary HR, bpm –0.7 –4.0 –3.3 –3.7 –3.0 –0.4 0.3
  PR, ms 1.1 0.7 –0.4 1.3 0.2 –0.2 –1.3
  QRS, ms –0.3 0.7 1.0 0.2 0.5 0.0 0.3
  QT, ms –0.4 9.3 9.7 8.6 9.0 6.9 7.3
  QTcF, ms –2.1 0.5 2.6 0.5 2.6 6.0 8.1
  QTcB, ms –3.0 –3.9 –0.9 –3.5 –0.5 5.5 8.5
  1. bpm, beats per minute; min, minimum; max, maximum; HR, heart rate; ms, milliseconds; QTcB, Bazett correction; QTcF, Fridericia correction; QTcI, individually heart rate-corrected QT interval.
  2. NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
  3. NEPA 600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).